Literature DB >> 21937424

The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.

Clinton D Orebaugh1, Jason M Fye, Scott Harvey, Thomas Hollis, Fred W Perrino.   

Abstract

Mutations in the TREX1 gene cause Aicardi-Goutières syndrome (AGS) and are linked to the autoimmune disease systemic lupus erythematosus. The TREX1 protein is a dimeric 3' DNA exonuclease that degrades DNA to prevent inappropriate immune activation. One of the most common TREX1 mutations, R114H, causes AGS as a homozygous and compound heterozygous mutation and is found as a heterozygous mutation in systemic lupus erythematosus. The TREX1 proteins containing R114H and the insertion mutations aspartate at position 201 (D201ins) and alanine at position 124 (A124ins), found in compound heterozygous AGS with R114H, were prepared and the DNA degradation activities were tested. The homodimer TREX1(R114H/R114H) exhibits a 23-fold reduced single-stranded DNA (ssDNA) exonuclease activity relative to TREX1(WT). The TREX1(D201ins/D201ins) and TREX1(A124ins/A124ins) exhibit more than 10,000-fold reduced ssDNA degradation activities. However, the TREX1(R114H/D201ins) and TREX1(R114H/A124ins) compound heterodimers exhibit activities 10-fold greater than the TREX1(R114H/R114H) homodimer during ssDNA and double-stranded DNA (dsDNA) degradation. These higher levels of activities measured in the TREX1(R114H/D201ins) and TREX1(R114H/A124ins) compound heterodimers are attributed to Arg-114 residues of TREX1(D201ins) and TREX1(A124ins) positioned at the dimer interface contributing to the active sites of the opposing TREX1(R114H) protomer. This interpretation is further supported by exonuclease activities measured for TREX1 enzymes containing R114A and R114K mutations. These biochemical data provide direct evidence for TREX1 residues in one protomer contributing to DNA degradation catalyzed in the opposing protomer and help to explain the dimeric TREX1 structure required for full catalytic competency.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21937424      PMCID: PMC3220555          DOI: 10.1074/jbc.M111.297903

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3'-->5' exonucleases.

Authors:  D J Mazur; F W Perrino
Journal:  J Biol Chem       Date:  1999-07-09       Impact factor: 5.157

2.  Structure and expression of the TREX1 and TREX2 3' --> 5' exonuclease genes.

Authors:  D J Mazur; F W Perrino
Journal:  J Biol Chem       Date:  2001-01-29       Impact factor: 5.157

3.  The human TREX2 3' -> 5'-exonuclease structure suggests a mechanism for efficient nonprocessive DNA catalysis.

Authors:  Fred W Perrino; Scott Harvey; Sara McMillin; Thomas Hollis
Journal:  J Biol Chem       Date:  2005-01-19       Impact factor: 5.157

4.  The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death.

Authors:  Dipanjan Chowdhury; Paul J Beresford; Pengcheng Zhu; Dong Zhang; Jung-Suk Sung; Bruce Demple; Fred W Perrino; Judy Lieberman
Journal:  Mol Cell       Date:  2006-07-07       Impact factor: 17.970

5.  A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein.

Authors:  M Höss; P Robins; T J Naven; D J Pappin; J Sgouros; T Lindahl
Journal:  EMBO J       Date:  1999-07-01       Impact factor: 11.598

6.  Dominant mutation of the TREX1 exonuclease gene in lupus and Aicardi-Goutieres syndrome.

Authors:  Jason M Fye; Clinton D Orebaugh; Stephanie R Coffin; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2011-08-01       Impact factor: 5.157

7.  Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome.

Authors:  Gillian Rice; William G Newman; John Dean; Teresa Patrick; Rekha Parmar; Kim Flintoff; Peter Robins; Scott Harvey; Thomas Hollis; Ann O'Hara; Ariane L Herrick; Andrew P Bowden; Fred W Perrino; Tomas Lindahl; Deborah E Barnes; Yanick J Crow
Journal:  Am J Hum Genet       Date:  2007-02-19       Impact factor: 11.025

8.  Gene-targeted mice lacking the Trex1 (DNase III) 3'-->5' DNA exonuclease develop inflammatory myocarditis.

Authors:  Masashi Morita; Gordon Stamp; Peter Robins; Anna Dulic; Ian Rosewell; Geza Hrivnak; Graham Daly; Tomas Lindahl; Deborah E Barnes
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

9.  Identification of a 3'-->5'-exonuclease that removes cytosine arabinoside monophosphate from 3' termini of DNA.

Authors:  F W Perrino; H Miller; K A Ealey
Journal:  J Biol Chem       Date:  1994-06-10       Impact factor: 5.157

10.  Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus.

Authors:  Yanick J Crow; Bruce E Hayward; Rekha Parmar; Peter Robins; Andrea Leitch; Manir Ali; Deborah N Black; Hans van Bokhoven; Han G Brunner; Ben C Hamel; Peter C Corry; Frances M Cowan; Suzanne G Frints; Joerg Klepper; John H Livingston; Sally Ann Lynch; Roger F Massey; Jean François Meritet; Jacques L Michaud; Gerard Ponsot; Thomas Voit; Pierre Lebon; David T Bonthron; Andrew P Jackson; Deborah E Barnes; Tomas Lindahl
Journal:  Nat Genet       Date:  2006-07-16       Impact factor: 38.330

View more
  25 in total

1.  Defects in DNA degradation revealed in crystal structures of TREX1 exonuclease mutations linked to autoimmune disease.

Authors:  Suzanna L Bailey; Scott Harvey; Fred W Perrino; Thomas Hollis
Journal:  DNA Repair (Amst)       Date:  2011-11-08

2.  Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase.

Authors:  Rebecca D Powell; Paul J Holland; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

3.  Heterozygous TREX1 mutations in early-onset cerebrovascular disease.

Authors:  N Pelzer; B de Vries; E M J Boon; M C Kruit; J Haan; M D Ferrari; A M J M van den Maagdenberg; G M Terwindt
Journal:  J Neurol       Date:  2013-07-24       Impact factor: 4.849

4.  Pattern recognition receptors in innate immunity, host defense, and immunopathology.

Authors:  Rahul Suresh; David M Mosser
Journal:  Adv Physiol Educ       Date:  2013-12       Impact factor: 2.288

5.  Aicardi goutières syndrome is associated with pulmonary hypertension.

Authors:  Laura A Adang; David B Frank; Ahmed Gilani; Asako Takanohashi; Nicole Ulrick; Abigail Collins; Zachary Cross; Csaba Galambos; Guy Helman; Usama Kanaan; Stephanie Keller; Dawn Simon; Omar Sherbini; Brian D Hanna; Adeline L Vanderver
Journal:  Mol Genet Metab       Date:  2018-09-07       Impact factor: 4.797

6.  Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease.

Authors:  Jessica L Grieves; Jason M Fye; Scott Harvey; Jason M Grayson; Thomas Hollis; Fred W Perrino
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

7.  Measuring TREX1 and TREX2 exonuclease activities.

Authors:  Wayne O Hemphill; Fred W Perrino
Journal:  Methods Enzymol       Date:  2019-06-08       Impact factor: 1.600

Review 8.  Autoimmunity: homeostasis of innate immunity gone awry.

Authors:  Hyon Ju Park; John P Atkinson
Journal:  J Clin Immunol       Date:  2012-10-11       Impact factor: 8.317

9.  Human DNA Exonuclease TREX1 Is Also an Exoribonuclease That Acts on Single-stranded RNA.

Authors:  Fenghua Yuan; Tanmay Dutta; Ling Wang; Lei Song; Liya Gu; Liangyue Qian; Anaid Benitez; Shunbin Ning; Arun Malhotra; Murray P Deutscher; Yanbin Zhang
Journal:  J Biol Chem       Date:  2015-04-08       Impact factor: 5.157

10.  The Arg-62 residues of the TREX1 exonuclease act across the dimer interface contributing to catalysis in the opposing protomers.

Authors:  Jason M Fye; Stephanie R Coffin; Clinton D Orebaugh; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2014-03-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.